Method of diagnosing blood clots using fibrin-binding proteins
AssigneeNeoRx Corporation
InventorsJohn M. Reno, Stephen W. Hadley, Marjorie A. Mohler
Life of this patent
Estimating the term…
Abstract
A fibrin-binding protein such as t-PA is labeled with a detectable substance, such as a radionuclide, and administered to a patient for diagnosis of blood clots and for monitoring the dissolution thereof during therapy. The detectable substance preferably is attached to t-PA through linkers which specifically bind to the portion of the t-PA protein responsible for enzymatic activity, thereby diminishing this activity while leaving the fibrin-binding property of the protein intact.
Claims11
A method for detecting a fibrin-platelet clot in vivo, comprising the steps of:
- (a) intravenously administering to a patient suspected of having a fibrin-platelet clot a radiolabeled thrombolytic protein wherein the radiolabeled thrombolytic protein's clot-dissolving activity is eliminated or reduced to a degree sufficient to prolong localization of the protein at a fibrin-platelet clot, compared to localization of a corresponding native protein at a fibrin-platelet clot, and the radiolabel is selectively attached through a linker that binds specifically to a portion of the thrombolytic protein other than a fibrin-binding domain;
- and p1 (b) detecting the biodistribution of the radiolabeled thrombolytic protein in the patient.
A thrombolytic protein having a radioisotope attached thereto, wherein the radioisotope is attached to said thrombolytic protein through a linker that binds specifically to a portion of the protein other than a fibrin-binding domain.
Dependencies are inferred from the claim text.